

Amendments to the Claims:

This listing of claims will replace prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-3 (canceled).

4. (previously presented): A composition comprising a therapeutically effective amount of a peptide of claim 20, or a pharmaceutically acceptable salt thereof, in association with at least one constituent selected from the group consisting of pharmaceutically acceptable carrier, diluent and excipient.
5. (original): The composition of claim 4, wherein said therapeutically effective amount is comprised between about 1 mcg and about 10 mg.
6. (previously presented): A method for treating or preventing a disease or condition associated with a disorder of glucose metabolism comprising administering to a subject in need thereof a therapeutically effective amount of the peptide of claim 20.
7. (original): The method of claim 6, wherein said disease or condition associated with a disorder of glucose metabolism is selected from diabetes mellitus of Type I or Type II and insulin resistance.
8. (original): The method of claim 7, wherein said condition is diabetes mellitus of Type I or Type II.
9. (original): The method of claim 7, wherein said condition is insulin resistance.
10. (original): The method of claim 6, wherein said disease or condition is a weight disorder or associated condition.
11. (original): The method of claim 10, wherein said weight disorder or associated condition

is selected from at least one of lowering weight, increasing satiety, post-prandially increasing plasma insulin levels, reducing blood glucose levels, and increasing pancreatic beta cell mass in said subject.


12. (original): The method of claim 11, wherein said lowering weight is from about 1 to about 10 kg.
13. (original): The method of claim 11, wherein said increasing satiety is of the order of about 10%.
14. (original): The method of claim 11, wherein said post-prandially increasing plasma insulin levels is of the order of about 10%.
15. (original): The method of claim 11, wherein said reducing blood glucose levels is of the order of about 10%.
16. (original): The method of claim 11, wherein said increasing pancreatic beta cell mass is of at least about 10%.
17. (original): The method of claim 6, wherein said peptide, or pharmaceutically acceptable salt thereof, is administered to said subject through an administration route selected from the group consisting of subcutaneous, intravenous, transdermal, oral, buccal and intranasal.
18. (original): The method of claim 6, wherein said subject is a human.
19. (previously presented): A composition comprising a prophylactically effective amount of a peptide of claim 20, or a pharmaceutically acceptable salt thereof, in association with at least one constituent selected from the group consisting of pharmaceutically acceptable carrier, diluent and excipient.

20. (currently amended): A GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof:

X-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Y (SEQ ID NO.1)

wherein:

X is a rigidifying hydrophobic acyl moiety as obtained from the corresponding carboxylic acid of general structure I:



wherein R1 is 2- or 3-lower alkoxy, 2- or 3-hydroxy, 2- or 3-amino, ~~2- or 3-N-arylamino~~ ~~2-N-phenylamino~~, 2,6-dihalo or 2,3,4,5,6-pentahalo and n = is 0 or 1, and

Y is selected from the group consisting of OH, NH₂ and Gly-OH.

21. (previously presented): The peptide of claim 20 wherein:

R1 = 2-hydroxy and n = 0,

R1 = 2-ethoxy and n = 0,

R1 = 3-methoxy and n = 1,


R1 = 3-amino and n = 1,

R1 = 2-N-phenylamino and n = 0,

R1 = 2,6-difluoro and n = 1, or


R1 = 2,3,4,5,6-pentafluoro and n = 1.

22. (currently amended): The peptide of claim 20 wherein the corresponding carboxylic acid is selected from the group consisting of




and


23. (previously presented): The peptide of claim 20 wherein the corresponding carboxylic acid is




24. (previously presented) The peptide of claim 20 wherein the corresponding carboxylic acid is



25. (previously presented) The peptide of claim 20 wherein the corresponding carboxylic acid is



26. (previously presented): The peptide of claim 20 wherein the corresponding carboxylic acid is



and Y is NH₂.